UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. by Barnes, Anna et al.
Barnes, A; Alonzi, R; Blackledge, M; Charles-Edwards, G; Collins,
D; Cook, G; Coutts, G; Goh, V; Martin, G; Kelly, C; Koh, DM;
McCallum, H; Miquel, ME; O’Connor, JP; Padhani, A; Pearson, R;
Priest, AN; Rockall, A; Stirling, J; Taylor, SA; Tunariu, N; van der
Meulen, J; Walls, D; Winfield, J; Punwani, S (2017) UK Quantita-
tive WB-DWI Technical Workgroup: consensus meeting recommen-
dations on optimisation, quality control, processing and analysis of
quantitative whole-body diffusion weighted imaging for cancer. The
British journal of radiology. p. 20170577. ISSN 0007-1285 DOI:
https://doi.org/10.1259/bjr.20170577
Downloaded from: http://researchonline.lshtm.ac.uk/4609953/
DOI: 10.1259/bjr.20170577
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
BJR
Cite this article as:
Barnes A, Alonzi R, Blackledge M, Charles-Edwards G, Collins DJ, Cook G,  et al. UK quantitative WB-DWI technical workgroup: consensus 
meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted 
imaging for cancer. Br J Radiol 2018; 91: 20170577.
© 2018 The Authors. Published by the British Institute of Radiology        
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution 4.0 Unported License http://  creativecommons. 
org/ licenses/ by/ 4. 0/, which permits unrestricted use, distribution and 
reproduction in any medium, provided the original author and source are 
credited.            
Guidelines & recommendations
uK quantitative WB-dWi technical workgroup: 
consensus meeting recommendations on optimisation, 
quality control, processing and analysis of quantitative 
whole-body diffusion-weighted imaging for cancer
1,2anna Barnes, 3roBerto alonzi, 4mattheW BlacKledGe, 5,6Geoff charles-edWards, 
4,7david J collins, 6,8Gary cooK, 9Glynn coutts, 6,8vicKy Goh, 10martin Graves, 11charles Kelly, 
4,12doW-mu Koh, 11hazel mccallum, 13marc e miquel, 14,15James o’connor, 16anWar Padhani, 
11,17rachel Pearson, 10andreW Priest, 12andrea rocKall, 18James stirlinG, 1,19stuart taylor, 
4,12nina tunariu, 20Jan van der meulen, 21darren Walls, 4,7Jessica Winfield and 1,19shonit PunWani
1Centre for Medical Imaging, University College London, London, UK
2Institute Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK
3Clinical Oncology, Mount Vernon Cancer Centre, Northwood, UK
4Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, Institute of Cancer Research, Sutton, UK
5Medical Physics, Division of Imaging Sciences and Biomedical Engineering, Guy’s and St Thomas’—NHS foundation Trust, King’s College 
London, London, UK
6School of Imaging Sciences and Biomedical Engineering, King’s College, London, UK
7MRI Unit, The Royal Marsden Hospital Foundation Trust, Surrey, UK
8Department of Radiology, Guy’s and St Thomas’ – NHS foundation Trust, London, UK
9MR Physics, The Christie NHS Foundation Trust, Manchester, UK
10Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
11Department of Radiology, Northern Centre for CancerCare, Newcastle upon Tyne Hospitals, NHS Foundations Trust, Newcastle upon 
Tyne, UK
12Department of Radiology, The Royal Marsden Hospital Foundation Trust, Surrey, UK
13Medical Physics, Barts Health NHS Trust, London, UK
14Division of Cancer Sciences, University of Manchester, Manchester, UK
15Department of Radiology, The Christie NHS Foundation Trust, Manchester, UK
16Paul Strickland Cancer Centre, Mount Vernon Cancer Centre, Northwood, UK
17Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
18PET Centre, King’s College, London, UK
19Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK
20Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
21Institute Nuclear Medicine, University College London, London, UK
Address correspondence to: Dr Anna Barnes 
E-mail:  anna. barnes1@ nhs. net
Received: 
08 August 2017
Accepted: 
11 October 2017
Revised: 
09 October 2017
https:// doi. org/ 10. 1259/ bjr. 20170577
2 of 12 birpublications.org/bjr Br J Radiol;91:20170577
BJR  Barnes et al
objective: Application of whole body diffusion-weighted 
MRI (WB-DWI) for oncology are rapidly increasing 
within both research and routine clinical domains. 
However, WB-DWI as a quantitative imaging biomarker 
(QIB) has significantly slower adoption. To date, chal-
lenges relating to accuracy and reproducibility, essential 
criteria for a good QIB, have limited widespread clinical 
translation. In recognition, a UK workgroup was estab-
lished in 2016 to provide technical consensus guidelines 
(to maximise accuracy and reproducibility of WB-MRI 
QIBs) and accelerate the clinical translation of quantita-
tive WB-DWI applications for oncology.
methods: A panel of experts convened from cancer 
centres around the UK with subspecialty expertise in 
quantitative imaging and/or the use of WB-MRI with 
DWI. A formal consensus method was used to obtain 
consensus agreement regarding best practice. Questions 
were asked about the appropriateness or otherwise on 
scanner hardware and software, sequence optimisation, 
acquisition protocols, reporting, and ongoing quality 
control programs to monitor precision and accuracy and 
agreement on quality control.
results: The consensus panel was able to reach consensus 
on 73% (255/351) items and based on consensus areas 
made recommendations to maximise accuracy and 
reproducibly of quantitative WB-DWI studies performed 
at 1.5T. The panel were unable to reach consensus on 
the majority of items related to quantitative WB-DWI 
performed at 3T.
conclusion: This UK Quantitative WB-DWI Technical 
Workgroup consensus provides guidance on maxim-
ising accuracy and reproducibly of quantitative WB-DWI 
for oncology. The consensus guidance can be used 
by researchers and clinicians to harmonise WB-DWI 
protocols which will accelerate clinical translation of 
WB-DWI-derived QIBs.
Table 1. +, agree but no consensus; *, agree with consensus; 
**, strongly agree with consensus
Harmonisation  
One acquisition protocol should be created to cover all 
quantitative (response) assessment of metastatic disease (“one 
size fits all”)
*
  Define Matrix size +
  Define Slice thickness *
  Define fat suppression technique *
  Define minimum number of b-values *
  Define min/max b-values *
  Whole body (head to mid-thigh) *
It should be possible to do quantitative (response) assessment on 
data from different scanners of the same manufacturer/model
**
It should be possible to do quantitative (response) assessment on 
data from different scanners of different manufacturers
*
An appropriately trained person should always perform a set 
up optimisation with a suitable test object.
**
A regular QC test should be carried out with a suitable test 
object.
**
It should be possible to define a post-processing pipeline that 
allows any ADC map from any scanner to be compared.
**
ADC, apparent diffusion coefficient; QC, quality control; 
introduction
Whole body MRI, including diffusion-weighted imaging 
(DWI), offers significant advantages over other cancer imaging 
modalities; combining a high soft tissue contrast and adaptable 
spatial resolution with “functional” imaging without exposure 
to ionising radiation. Fuelled by recent technological advances, 
the use of whole body MRI in oncology is rapidly increasing, 
both for clinical research and for routine clinical imaging of 
specific indications (e.g. multiple myeloma).1 Whole body DWI 
(WB-DWI) enables assessment of RECIST non-measurable 
disease foci such as bone metastases2 and, as well as depicting 
anatomy, DWI provides microstructural information3 that can 
be correlated with tissue metabolism.4
Quantitative evaluation of DWI provides a measure of the 
average apparent diffusion coefficient (ADC) of water within a 
voxel. Differences in ADC between voxels reflect differences in 
the cellular composition (microstructure) of individual voxels. 
Despite many recent publications demonstrating the poten-
tial of ADC to act as a quantitative imaging biomarker (QIB) 
for oncology,5–11 WB-DWI-derived ADC assessment has not 
become widely used in clinical practice, and has struggled with 
adoption as the primary endpoint biomarker in multicentre 
trials. Key factors  limit  generalizability of WB-DWI, these 
include: (i) the complexity of optimising WB-DWI protocols to 
produce artefact free images; (ii) the lack of standardization of 
WB-DWI acquisition parameters; and (iii) heterogeneity in deri-
vation and interpretation of ADC values.12
To address these factors and promote research and clinical 
applications of WB-DWI, there is a need to agree hardware 
and software requirements, and provide sequence optimiza-
tion, acquisition, reporting and quality control (QC) guidance 
for maximising accuracy and reproducibility.11–16 To address 
this challenge, a group of experts (UK Quantitative WB-DWI 
Technical Workgroup) was convened from cancer centres 
around the UK with subspecialty expertise in quantitative 
imaging and/or the use of WB-DWI within clinical and/or 
research practice.
This document is the output from this group and is intended 
to act as guidance for clinicians, radiographers and MR phys-
icists/clinical scientists who are considering development/
implementation of quantitative WB-DWI (qWB-DWI) for 
clinical trial or routine clinical use.  The  main  recommenda-
tions from this review are listed in Tables 1–3.
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Table 2. Bolded items 1.5T and 3T, Consensus result in columns for routine clinical/multi-centre trial. +, agree but no consensus; 
*, agree with consensus; **, strongly agree with consensus. Italics indicate round table consensus
Clinical Trial
Acquisition Protocol    
  Do not use intrinsic body coil as a receiver coil ** **
  Axial from cranial vertex to mid-thigh ** **
  Total acquisition time < 30 mins ** **
  Free breathing    
  In-plane acquisition pixel size ≥ 3 × 3 mm (matrix 128 × 128 FoV ~ 380 × 420) * *
  Minimum slice thickness = 5 mm * *
  40–50 slices per bed station * *
  Single shot EPI (Contiguous slices, interleaved) ** **
  Parallel imaging (Reduction factor = 2)    
  Fat suppression method = STIR (160 ms <TI < 180 ms) * **
  Minimum number of b-values = 2    
  b-values = 50–100 s mm–2, 800–1000 s mm–2 * *
  Diffusion weighted images: trace weighted + +
  Number of averages = 3 (more at higher b value if possible, dependent on grad encode scheme) + *
  TE < 95 ms    
  TR ≥ 5×T1 of tissue of interest    
Optimisation Protocol    
  Always perform initial optimisation on suitable test object: * **
   minimally diffusing, (or doped water) * **
   known ADC values, * **
   controlled temperature (e.g. iced water phantom) * **
   larger than total number of slices (per bed station) * **
  Minimise the:    
   Static field distortion * **
   eddy-current induced distortion * **
   ghosting ** **
   Optimise fat suppression on human volunteers * **
   Assess repeatability and reproducibility for multi-centre trials on human volunteers + **
Routine Quality Assurance    
  Routine QC measurements should be performed and recorded ** **
   Not necessary to test daily or weekly + +
   every 3 months * *
   after software/hardware upgrades ** **
   after repairs/maintenance * *
  Routine Quality control measurements should be performed with a suitable test object:    
   iced water + *
   sugar/(doped)water at room temperature + *
Routine Quality control tests    
   ADC linearity in Z-direction across all slices in bed station + *
(Continued)
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Clinical Trial
   Static field distortion + *
   Eddy-current induced distortion + *
   Ghosting + *
ADC, apparent diffusion coefficient; FOV, field of view;  TE, echo time; TR, repetition time; QA, quality assurance; QC, quality control; STIR, short 
tau inversion-recovery. 
Table 2. (Continued)
Table 3.  Bolded items staging and response assessment.  +, 
agree but no consensus; *, agree with consensus; **, strongly 
agree with  consensus
Processing and Analysis  
  Apply SNR threshold before calculating ADC +
  Calculate ADC map on each bed station separately before 
stitching
*
  Voxel-wise mono exponential/no b = 0 model *
  Do not use bi-exponential or stretched exponential model **
  Use VOIs to extract ADC values from multiple lesions +
  Use low b-value image to delineate VOI *
  Do not extract histogram characteristics *
  Do not use absolute thresholding to define VOI/ROI *
Visualisation and Reporting  
  Report mean ADC *
  Report median ADC *
  Report SD of ADC +
  Report volume of VOI +
  Report alongside other modalities (US, CT, PET) +
  Do not use RECIST 1.1 inspired reporting *
  Report % change in mean/median ADC values *
  View ADC maps of each bed station separately +
  View ADC maps as whole body images *
  View ADC maps in all 3 directions *
  View ADC maps alongside b-value images *
  View ADC maps alongside T2w and T1w images *
  ADC maps should not be fused with T2w, T1w images *
  High b-value signal intensity images should be viewed using 
a rotating Maximum Intensity Projections (MIPs)
+
  Not necessary to produce a >b =1000 s mm–2 image *
  View previous ADC maps for longitudinal studies *
  Use rigid body image registration for longitudinal studies +
ADC, apparent diffusion coefficient; FOV, field of view;   QA, 
quality  assurance; QC, quality control; STIR, short tau inversion-
recovery; TE, echo time; TR, repetition time; STIR, short tau inversion-
recovery.
methods and materials
The consensus method
A consensus approach was developed based on the RAND/
UCLA Appropriateness Method. This approach aimed to obtain 
consensus agreement regarding best practice for the implemen-
tation of qWB-DWI (http://www. rand. org/ pubs/ monograph_ 
reports/ MR1269. html). This method includes a combination 
of remote and face-to-face consensus rounds and combines the 
best available scientific evidence with the collective judgment 
of experts to yield statements regarding the appropriateness of 
relevant aspects of the topic under investigation. It is particu-
larly suited to areas with a relative paucity of high quality level 
1 evidence (e.g. randomized controlled trials) or, if the evidence 
is available, it does not contain sufficient detail to guide prac-
tice applicable to the range of patients seen in everyday clinical 
practice.
When using this method, appropriateness levels are used to 
communicate the perceived balance between risks/costs and 
benefits of each item under discussion. Our approach followed 
the RAND/UCLA Appropriateness Method as it is set out in the 
user’s manual throughout the process, as much as possible.17
Panel selection
Leading clinicians, radiographers and scientists from the UK, 
with known subspecialty expertise in quantitative imaging and/
or the use of imaging to inform treatment, were approached (MR 
physics, MR radiology, nuclear medicine, radiotherapy physics, 
oncology). An independent chair was selected, with experience 
using formal consensus methods to develop clinical guidelines. 
A total of 25 panel members were confirmed.
Construct of the questionnaire
An extensive questionnaire containing 369 items was 
constructed between August and November 2015. The first 
draft was produced by four panel members with a background 
in MR physics.
The questionnaire was split into six main areas for consid-
eration—initially defining the scope and requirement for (i) 
harmonisation; followed by addressing specific items needing 
consensus to achieve harmonisation goals, specifically: (ii) 
hardware specification, (iii) optimization, (iv) routine quality 
assurance (QA), (v) acquisition parameters and (vi) analysis and 
visualisation requirements. Within each section questions differ-
entiated requirements for multicentre trials versus routine clin-
ical practice, and between 1.5 and 3T magnetic field strengths.
(i) Harmonisation: This section was structured to identify 
critical requirements for a qWB-DWI protocol, and thereby 
provide a common standard; extending from desired 
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applications to analysis and personnel needed to implement 
the technique.
(ii) Hardware Specifications: This section asked questions to 
ascertain the minimum specifications that an MR scanner 
must have in order to acquire qWB-DWI and how to deal 
with variability in MRI hardware across sites.
(iii) Site optimisation: These questions were split into two groups; 
one for optimising a clinical service and the second for a trial 
site.
(iv) Routine QA: These questions were split into two groups; 
one for routine QA and control for a clinical service and the 
second for a trial site.
(v) Acquisition parameters: This section lists some basic 
acquisition parameter ranges based on current practice 
in centres using qWB-DWI protocols. Topics included fat 
suppression technique, maximum and minimum b-values, 
slice thickness, in-plane voxel sizes, imaging bandwidth and 
number of signal averages.
(vi) Analysis, visualisation and reporting: This section considers 
analysis of the images including the processing of the data, 
such as intensity thresholding or motion correction prior to 
the ADC calculation, as well as how the data is visualised in 
the most useful way for a radiologist to report.
First-round questionnaire completion before the 
meeting
All panel members were sent the questionnaire as an online 
survey (29 February 2016 to completed by 24 March 2016), with 
relevant literature on the RAND/UCLA appropriateness method 
and technical articles on quantitative WB-DWI via the project 
website (https:// sites. google. com/ site/ wbadcconsensus/ home). 
They were instructed to score each item on a Likert scale18 
between 1 (strongly agree) and 5 (strongly disagree). A midpoint 
score of 3 indicated not necessary (or it does not matter) and a 
further category 6 (do not know) was used for the member to 
indicate that they did not have sufficient expertise to answer the 
question.
The questionnaire responses were collected and summarised by 
the consensus co-ordinator. A complete list of questions and modal 
answers are listed in Appendix A. Cell is colour coded grey if no 
consensus was reached, the text indicates the value of the mode 
answer of the panel.
Face to face meeting format
The meeting was convened for one day in London, 12 April 
2016. 23 panelists attended (2 were unable to attend the face-to-
face discussions). The co-ordinator convened the meeting and 
documented key points of discussion. The whole meeting was 
audio recorded in order to check points in the discussion when 
preparing the manuscript.
At the beginning of the consensus meeting, selected expert panel 
members presented on the following topics: DWI in oncology, 
QA in DWI and practical aspects of performing whole-body 
DWI. Speakers were asked to summarise the evidence in the 
given area and to highlight areas of controversy.
Thereafter, for each individual question included in the ques-
tionnaire, a summary of the panel scores was presented and the 
topic discussed by the panel. After the discussion, the panelists 
rescored that item and were free to maintain or change their 
original response from the prior on line completion stage.
Four questions were reworded during the panel discussion to 
improve clarity. Six questions were added and scored during 
the meeting. 12 questions were removed during the meeting. In 
particular, it was decided to remove questions 6 and 7 regarding 
the use of whole body imaging as a tool for the assessment 
of other diffuse disease such as inflammation, i.e. there was 
consensus on using this technique only for wide-spread onco-
logical disease. Questions 57  and  63 were also removed, since 
it was felt the use of open bore magnets to measure quantitative 
WB-DWI was a moot point, i.e. there was consensus not to use 
this type of scanner. Questions 360–367 were removed owing 
to the panel’s general agreement that there was currently a lack 
of data regarding the usefulness of using percentage change in 
ADC values as a response criteria or at what point it should be 
measured post-treatment to be able to answer these questions, 
i.e. there was consensus that this should not be used as a criteria 
to report. Questions 94–97 regarding the tests to be performed 
during acquisition optimisation were added during the discus-
sion. One more question was added to the routine QA/QC 
section to allow the option of performing QC test quarterly, and 
four items that included the title “clinical scientist” were changed 
to “appropriately trained personnel”. In all cases, these changes 
were made with full agreement of the members of the panel and 
scored during the meeting.
Interpretation of the results
The results of the second round of scoring were interpreted 
according to the RAM user’s manual,17  i.e. only those items 
scored (on the scale 1–5 and not 6) by at least eight panel 
members were included in the results (every single item met this 
criteria). Consensus was defined as described in the user manual 
and listed below in Table 4.
The modal answer is calculated for each question and then the 
number of answers outside of the 2-point range that includes the 
Table 4. Key to calculate how consensus is defined; such that 
if there are more than the number of answers in the second 
column that are not within the mode response then there is 
NO CONSENSUS. This translates roughly to 70–80% of agree-
ment between responders
Number of 
delegates
Number of delegates whose 
answer is outside the mode
8–10 No more than 2
11–13 No more than 3
14–16 No more than 4
17–19 No more than 5
20–22 No more than 6
23–25 No more than 7
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modal answer (agree score, 5–4; not necessary score, 3; disagree 
score, 2–1) are counted. If there are more than a certain number 
(Table 4 above) outside the 2-point range answer, then the ques-
tion is deemed to have reached “no consensus” as stated in the 
RAND/UCLA manual p. 5817 for a scale of 1–9 where the corre-
sponding 3 point ranges are agree, (1–3) not necessary (3–6) 
disagree (7–9).
results
Supplementary  material  (Supplementary  material available 
online.) includes the complete list of questions and modal scores 
before and after the panel discussion. Cells colour coded white 
indicate that consensus was reached and grey indicates that it 
was not. The text indicates the value of the mode answer within 
the group.
Consensus was achieved on 197/369 prior to and 255/351 
following the consensus meeting. Tables 1–3 lists the items whose 
modal answer was agree (*) or strongly agree (**) with consensus 
or agree with no consensus (+). Areas for which consensus were 
not reached are listed in Table  5 where the modal answer not 
necessary =(o) or disagree = (x).
Harmonisation
Table 1a highlights the consensus amongst the expert panel on 
the general need for harmonisation of MR protocols, optimisa-
tion, QC and post-processing of qWB-DWI studies.
Although aspirational, the ability  to  compare ADC values 
(without reference to the hardware or software by which it was 
acquired) was unanimously agreed as a goal of harmonisation. 
The panel defined the scope of the consensus as pertaining to 
the use of qWB-DWI for oncological imaging rather than the 
assessment of other diffuse diseases, such as arthritis. Answers 
to questions in each subsequent section pertain to the aspiration 
and scope as defined by the panel.  On the particular question 
“a clinical scientist should perform the site set-up optimisation” 
the panel came to a mutual agreement that “clinical scientist” 
(a protected professional title) should, therefore, be replaced 
by “an appropriately trained person”. During further discus-
sion,  complete agreement was also reached on the fact that 
consistent and comprehensive training in specialist quantitative 
MRI techniques will result in high quality and consistent image 
quality. A national training program could provide recommen-
dations based on this consensus paper and practical hands-on 
experience of: site set-up and optimisation; routine QA; acquisi-
tion/scanning protocols; patient set-up; quantitative metrics; and 
statistics.
Hardware specification and acquisition protocol/
optimisation protocol/routine QA
Table  2 provides statements relating to consensus on specific 
acquisition parameters, optimization procedures and QA 
when setting up quantitative WB-DWI. Items that are 
bolded in  Table  2  reached consensus at both 3T and 1.5T 
field strength for routine clinical and multicentre trial 
Figure 1. Typical patient set up for a whole body (eyes to thighs) MRI scan (a) Siemens Healthineers (Erlangen, Germany)  (b) 
GE Healthcare (Waukesha, Wisconsin, USA) (c) Philips Healthcare (Koninklijke, The Netherlands).
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applications; non-bold items achieved consensus for 1.5T 
only for routine clinical scanning and multicentre trials. 
Figure  1 shows a typical whole body MRI scan patient 
set-up for the threee main scanner manufacturers.
Hardware specification and acquisition protocol 
The majority of the panel (those that were already familiar with 
acquiring qWB-DWI) felt strongly that robust qWB-DWI at 
1.5T was achievable but it was acknowledged that  (Table 5) there 
are challenges for translating these protocols to 3T platforms and 
that more evidence needed to be gathered on quantitative appli-
cations at 3T. In panel, consensus reflected previous recommen-
dations,12,19–22 that WB-DWI is performed axially at multiple 
anatomical stations from head to midthigh (~4–5 sections) each 
acquired using the same MRI parameters  and taking approxi-
mately 30 min in total. In order to acquire maximal SNR of 
DWI within a 30 min time-frame, this will typically limit scans 
to the acquisition of two b-values only: 50–100 and 800–1000 
s  mm–2. However, there are current scanner acquisition plat-
forms such that b = 0 s  mm–2  is collected by default in order 
to calculate ADC maps at the scanner console. There are, then, 
two options recommended by the panel; collect three b-values 
(at the expense of increased time for acquisition) where the 
second b-value should be between 50 and  200 s  mm–2; collect 
two b-values (not b = 0 s mm–2) and perform the ADC calcula-
tion offline. Fat suppression should be used to remove unwanted 
signals from fat and multiple averages of each image to be 
acquired. Anecdotal evidence from panel members frequently 
using WB-DWI allowed an additional recommendation that the 
patient breathes freely during the diffusion-weighted acquisition. 
Basic acquisition parameters provided in Table 2 were agreed as 
a starting point for optimization at sites that have not previously 
performed WB-DWI. It was also agreed, that if not possible to 
implement even these basic parameters, then sites should not 
attempt quantitative WB-DWI, particularly for the purposes of 
multicentre trials.
Although the panel supported the use of 3T for WB-DWI, it 
noted that there is currently insufficient evidence to recom-
mend standardised basic acquisition protocols. Instead the panel 
recommends that a suitably trained person should carefully opti-
mise all acquisition parameters listed in  Table 2 for any partic-
ular 3T system.
Protocol optimisation:
Consensus recommendations for DWI as an oncology 
biomarker recommend that protocols should be “optimised to 
maximise SNR, minimise artefacts from ghosting and distor-
tion and optimise fat suppression”.11 This panel also reached 
the same consensus. For multicentre trials, the panel recom-
mended, as essential, protocol development using the param-
eters listed in Table 2 as a starting point, with the appropriate 
phantoms listed to interrogate the effects of eddy current-in-
duced distortion and fat suppression. The reader is directed 
to an excellent review of these optimisation steps and their 
practical implementation described by Winfield et al23 and the 
latest IPEM report “Quality Control and Artefacts in Magnetic 
Resonance Imaging (Update of IPEM Report 80) – Report 
112”.19
Routine QA: 
There was a clear distinction in number of QA items reaching 
consensus between routine clinical scanning and multicentre 
trials (3 vs 8 out of 10). While performing additional specific 
QA tests to support a multicentre trial was considered manda-
tory, there was no consensus on the need for additional specific 
QA in routine clinical practice. In general, the panel felt most 
MRI departments in the UK will have a regular routine QA 
strategies together with preventative maintenance contract with 
manufacturers/third party providers, which with optional addi-
tional coil checks on a daily/weekly basis (time and staff permit-
ting)  should be sufficient for routine clinical applications. The 
panel’s recommendation was to carry out routine QC tests listed 
in Table 2 (measurements for eddy current distortion, ghosting 
and ADC linearity in the z-direction) for both routine clinical 
and multicentre trials every 3 months and/or after major soft-
ware or hardware upgrades or repairs. The panel cited the work 
by the American College of Radiology and the Association of 
American Physicists in Medicine (AAPM) on the practice and 
interpretation of regular QC tests and would seem a good place 
to start.20,21
Processing and analysis/visualisation and reporting
Table  3  relates to statements where positive consensus was 
reached relating to processing, analysing, visualisation and 
reporting of quantitative WB-DWI. The items that are bolded 
and italicized in  Table  3 are applicable to both staging and 
response assessment oncological applications, otherwise they are 
only applicable to response assessment.
Processing and analysis: 
This section achieved the least number of items of consensus 
both before and after the panel meeting. Those items on which 
the panel did reach consensus can be summarised as “keep 
it simple”. As with other quantitative imaging techniques, no 
consensus was reached with regard to the methodology for 
delineation of disease in WB-DWI, whether manually or by 
some automated/semi-automated segmentation process. Nor 
was there consensus on whether whole-body disease burden 
was preferred over a RECIST inspired approach of five target 
lesions as suggested by Perez-Lopez et al.22 By extension, there 
was lack of consensus on which, if any, ADC statistics should be 
obtained from within the delineated disease (e.g. standard devi-
ation, kurtosis or skewness of ADC values within the tumour 
volume) or the actual tumour volume itself. The panel felt that 
whilst some published literature has demonstrated prelimi-
nary evidence that such statistics offer quantitative approaches 
for assessment of patient prognosis24 and heterogeneous treat-
ment response,25,26 these methods are still in their infancy and 
required further validation before consensus could be achieved. 
All major manufactures provide workstation applications for 
post hoc analysis Philips Healthcare  (Vistar), Siemens Health-
ineers  (Syngo.Via), GE Healthcare  (AW) and there are several 
third party applications OSIRIX (pixmeo, Geneva, Switzerland), 
Mirada Medical (Oxford, England), as well as open-source solu-
tions such as ImageJ (National  Institue  for  Health,  USA). All 
provide ADC map calculations as well as ROI/VOI toolboxes 
and image intensity thresholding applications, as well summary 
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Table 5. Summary of areas of no consensus. +modal answer agree; o, modal answer notnecessary;  x, modal answer disagree;
Standardisation– No consensus  
Acquisition  
  A minimum reconstructed pixel size at 1.5T and 3T +
  A minimum of 3 averages per bb-value at 1.5T and 3T for routine clinical +
  The gradient encoding scheme to be 3 orthogonal directions. o
  The fat suppression technique to be STIR at 3T only o
  The acquired slice thickness to be no less than 5 mm at 3T only +
  A maximum axial FoV at 3T o
  A minimum acquisition pixel size at 3T only +
Optimisation  
  No consensus for routine clinical imaging at 1.5T and 3T to  
  Perform repeatability and reproducibility scans on normal volunteers o
  Perform optimisation of sequence on a sugared water test object at room temp +
Routine QA and QC  
No consensusfor routine clinical imaging at 1.5T and 3T to  
  Perform monthly tests o
  The type of tests that should be done or how to do them  
   ADC linearity in the Z-axis +
   Measure B0 distortion o
   Measure the eddy current distortion o
   ADC linearity in 3 different directions +
  What test object should be used  
   Iced water phantom +
   With known biologically relevant ADC values +
   Minimallydiffusing medium (e.g. oil) o
No consensus for research trial imaging at 1.5T and 3T to  
  Performdaily or weekly tests o
  The type of tests that should be done  
   ADC linearity in three directions o
Analysis Visualisation & Reporting  
No consensus was reached for basic ADC quantitation on whether  
   A base signal intensity noise level should be set prior to ADCcalculation +
   To perform a bed station signal intensity normalisation over thewhole body prior to ADC calculation x
No consensus was reached for disease staging and response assessment on how  
  To define a ROI/VOI  
   Geometric o
   Set threshold based on Max value o
   Use another MR weighted image to free draw VOI/ROI (staging only) o
  Whether whole body disease burden would be a useful measure o
  Reporting the standard deviation for each VOI/ROI +
  Specifying a percentage value of increase or decrease of tumour volume onsome ADC threshold to indicate positive or negative 
response respectively.
+
(Continued)
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statistic extraction tools.  While nuclear medicine applications 
have been used for decades to assess quantitative 3D sectional 
imaging, main radiology applications such as X-ray CT and 
MRI have traditionally been reviewed on picture archiving 
and communication system (PACS) viewing stations with little 
or no added functionality. In truth, until this functionality has 
been added to PACS there will be a slow uptake in busy clinical 
National Health Service (NHS) imaging departments of specialty 
reporting tools that require additional workstations.
Visualisation and reporting: 
The paper by Padhani et al11 “METastasis Reporting and Data 
System for Prostate Cancer: Practical Guidelines for Acquisi-
tion, Interpretation, and Reporting of Whole-body Magnetic 
Resonance Imaging-based Evaluations of Multiorgan Involve-
ment in Advanced Prostate Cancer  (APC)”27 set-out to estab-
lish minimum acceptable technical parameters for WB-MRI in 
APC: machine set-up, sequence specifications, routine QA/QC 
and radiographic aspects. Recommendations included; skull 
base to midthigh coverage, STIR fat suppression, 5–7 mm slice 
thickness, two b-values 50–200 and 800–1000 s mm–2, mono-ex-
ponential ADC calculation, MIP and coronal display of high 
b-value image. Although there was agreement with this guid-
ance on WB-DWI visualisation and reporting27–29 on most items 
that overlapped; the panel did not reach consensus on the more 
advanced specifics of: fusion of multiparametric data sets  and 
co-registration software functionality, and use of the inverted 
grey  scale maximum intensity projections of the high b-value, 
etc. The panel acknowledged the recommendations for the visu-
alisation and reporting of WB-DWI data as included in the paper 
by Padhani et al.27 See Figure 2 for an example of a typical data 
set acquired on a 1.5T Siemens Magnetom scanner.
discussion
Quantitative WB-DWI is still only available clinically in a few 
centres for the investigation of disseminated cancer, although 
numbers and publications are increasing it has yet to achieve 
widespread adoption. To address the challenges faced in more 
generalised dissemination of WB-MRI across sites, a panel of 23 
experts met to provide a set of recommendations based on the 
consensus RAND/UCLA method on the use and acquisition of 
quantitative WB-DWI.
Given the increasing number of sites with both a research and 
clinical interest in WB-MRI within the UK; this consensus was 
aimed specifically at deriving a UK-specific strategy on harmon-
ising quantitative WB-DWI. However, many of the panel 
members have previously taken part in international consensus 
panels and have an international reputation providing a non-UK 
centric perspective on the subject and the outcomes of a UK 
approach to harmonisation will also have relevance to other 
country/international organisations developing such guidelines.
Broadly, areas of consensus were: the need for specialist training, 
standardised guidelines for initial optimisation of sequence 
Figure 2. Example of a qWB-DWI data set from a patient with advanced prostate cancer (a) b = 50 s mm–2, (b) b = 900 s mm–2 and 
(c) corresponding ADC map calculated using a mono-exponential model. ADC, apparent diffusion coefficient; WB-DWI, whole 
body diffusion-weighted MRI.
  ADC values should be reported alongside  
   Biopsy samples o
   Blood serum markers o
   Other modality images (response assessment only) +
  Using arotating greyscale MIP of whole body ADC map similar to whole PET scan o
  The need for image registration for longitudinal reporting +
Table 5. (Continued)
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parameters, standardised routine QC tests and test objects, stan-
dardised acquisition parameters to ensure best SNR and patient 
comfort; the value of widespread use of quantitative WB-DWI 
for follow-up imaging in disseminated malignant disease; the 
use of the mono-exponential model for calculation of ADC; the 
use of summary statistics of ADC values for reporting, although 
ADC thresholds for “treatment response” and “disease progres-
sion” still need to be established. Consensus recommendations 
based on these areas are listed in Tables 1–3.
Overall, a good level of agreement was achieved for quantitative 
WB-DWI at 1.5T, but it was acknowledged that there are chal-
lenges of translating these protocols to 3T platforms and that 
more evidence from experienced users was needed. In  partic-
ular, the need to understand the role of the latest technologies 
in optimising the DWI signal: parallel imaging, fat suppres-
sion techniques, eddy current distortion corrections and static/
dynamic field inhomogeneities. Areas for which consensus were 
not reached (Table 5) included implementation of the latest tech-
nology and novel analysis methods associated, the exact nature 
of the routine QC tests for routine clinical practice and how they 
should be performed and how often; and the metrics used to 
measure, characterise (histogram and associated statistics) and 
visualise ADC maps.
There exists the criticism that “many imaging biomarkers, remain 
confined to the academic literature without real application 
owing to a lack of efficient and effective strategies for biomarker 
translation”.12 The European Organisation for Research and 
Treatment of Cancer (EORTC) position paper concluded that 
MRI offers a good ‘‘one size fits all’’ solution for patients who 
do not have substantial non-bone disease to assess therapy effec-
tiveness30 and the recent interest in using MRI for radiotherapy 
treatment planning31 and the advent of MRI Linacs32 only high-
lights the need for establishing the robustness of this technique. 
This document has been prepared in answer to papers citing the 
need for comparative multimodal studies, to provide prospective 
quantitative data from treatment–response assessment settings.27 
This paper describes the use of the RAND style method17 to 
achieve consensus on a range of aspects of a clinical procedure, 
quantitative WB-DWI, in order to obtain best practice that can 
be shared amongst the diagnostic radiology community in the 
UK. This publication should be received as a starting point for 
sites developing quantitative WB-DWI protocols that can then 
contribute to multicentre studies and enable clinical studies for 
specific emerging indications (e.g. multiple myeloma).
Future work
The panel recognized the need to develop and promote training 
opportunities for radiologists, MR physicists and radiographers 
specifically for the implementation, QA, reporting and analysis 
of whole body DWI for quantitative measures.
The group expects to produce a library of useful QA proce-
dures  and tests and establish tolerances for each of these tests 
across scanner platforms, such that the user of a specific platform 
(a) can determine whether their platform is performing within 
acceptable tolerances in order to be able to apply quantitative 
whole body DWI for clinical decision-making and (b) can take 
remedial measures, where possible, to correct any out of toler-
ance results. It is the intention of the first author (supported by 
an NIHR fellowship) to co-ordinate and gather further data from 
already participating clinical trial centres33 to establish these 
tolerances.
There is also much needed, ongoing, NIHR-funded work devel-
oping post-processing techniques (e.g. those originally devised 
on T1 and T2 weighted data of the brain34,35 and MR manufac-
turer independent analysis tools to visualize ADC maps),36 the 
output of which is expected to standardize methods and help 
delivery of the QC tests recommended in Table 2. 
In summary, using the RAND/UCLA consensus method, a 
UK-based panel was able to make recommendations to provide a 
robust and reproducible quantitative WB-DWI protocol suitable 
for 1.5T to be used routinely to evaluate conditions of dissemi-
nated cancer before and after treatment. It is the panel’s intention 
to meet again in 3 years time to update the document.
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